Blockchain Registration Transaction Record

Helus Pharma Shareholders Approve Name Change and Board

Helus Pharma shareholders approve name change from Cybin Inc. and elect new board. The company advances novel serotonergic agonists for depression and anxiety.

The approval of the legal name change from Cybin Inc. to Helus Pharma Inc. marks a pivotal moment for the company as it transitions from a clinical-stage discovery firm to a commercial-ready pharmaceutical entity. This shift is significant for investors and patients alike, as it signals the company’s confidence in its pipeline of novel serotonergic agonists (NSAs) targeting depression and anxiety. With HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, Helus Pharma is positioning itself to address a massive unmet need in mental health. The Breakthrough Therapy Designation for HLP003 from the FDA underscores the potential of its approach. As mental health disorders affect millions worldwide, the success of Helus Pharma’s NSAs could revolutionize treatment options, offering new hope for patients who have not responded to existing therapies. Moreover, the company’s global operations across Canada, the U.S., the U.K., and Ireland highlight its ambition to become a leader in the neuropsychiatric space. For investors, the rebranding and corporate restructuring may enhance visibility and attract new capital, driving further development. Ultimately, this news matters because it represents a step forward in the fight against mental illness, with the potential to improve lives and create significant shareholder value.